TME Pharma

Aram Mangasarian, PhD, MBA


Aram Mangasarian was appointed CEO of TME Pharma (formerly NOXXON Pharma) in July 2015. He has transformed the company into a lean, publicly quoted company focused on targeting the tumor microenvironment to improve the treatment of solid tumors. Aram brings over twenty years experience in the biotechnology industry to TME Pharma. Under his leadership, the company has raised close to €65 million. 


Prior to joining TME Pharma in May 2010 as Chief Business Officer, Aram served as Vice-President Business Development for Novexel where he concluded a €150 million licensing agreement including a €75 million upfront payment with Forest Laboratories (NYSE:FRX) for North American rights to a beta-lactamase inhibitor now known as avibactam. Aram was a member of the management team that negotiated the subsequent acquisition of Novexel by AstraZeneca (NYSE:AZN) for up to $505 million.

Aram began his career at ExonHit Therapeutics (now Eurobio Scientific, Euronext:ALERS), where he served in a variety of roles eventually heading the business development function as Vice-President. He concluded a number of important agreements for ExonHit, in particular the $30 million strategic alliance with Allergan. Aram has served as a non-executive member of the boards of two Scandinavian biotechs, Isofol Medical AB, based in Sweden, and C10 Pharma, based in Norway.

Aram received a B.S. from the University of Wisconsin-Madison in biochemistry, molecular biology and English literature, a PhD in Biology from the University of California-San Diego for research carried out at the Salk Institute and an MBA from INSEAD.

Jarl Ulf Jungnelius, MD, PhD


Jarl Ulf Jungnelius, MD, PhD joined the company as Chief Medical Officer in February 2017. He is an oncologist with more than 25 years of clinical and research experience at both large pharmaceutical companies and academic organizations.


Jarl Ulf was CEO of Isofol Medical AB. He also serves on boards of Biovica International, CarpoNovum, Oncopeptides and Ryvu Therapeutics. Jarl Ulf held important responsibilities in the clinical development of several successful oncology drugs, including Abraxane®, Gemzar®, Alimta® and Revlimid®. He worked at Celgene from 2007 to 2014 where he served as Vice President of Clinical Research and Development, Solid Tumors. Prior to that post Jarl Ulf held leadership positions at Takeda, Pfizer, Eli Lilly & Company and VAXIMM, where he was responsible for clinical development of oncology programs as well as being involved in business development.

He received both a Bachelor of Science degree and his MD from the Karolinska Institute in Stockholm Sweden.

Dr. Heike Balzer

Senior Vice President


Dr. Heike Balzer joined TME Pharma in 2000 and has served as Senior Vice President Finance since 2006. She is responsible for financial reporting, corporate controlling, non-dilutive project funding, corporate taxes, and insurance management. 


Heike has been involved in raising more than €190 million in financing transactions via diverse financing vehicles. Prior to TME Pharma, Heike held several positions at medium sized companies in the service sector, where she led reorganization and turnaround projects and was in charge of implementing business know-how in technology driven entities. She also lectures business administration and controlling at the University of Potsdam. Heike holds a Doctor in Economics from the University of Leipzig.

Dr. Dirk Eulberg, MBA

Senior Vice President

Project Management & Preclinical Development

Dr. Dirk Eulberg, MBA, serves as Senior Vice President Project Management and Preclinical Development. He joined the company in 2000 to establish an automated discovery process of Spiegelmers and has been responsible for the development of Spiegelmers, from lead identification and optimization via pharmacological profiling and preclinical development into the clinic to Proof-of-Concept in patients. 


Dirk successfully brought three drugs from discovery to the clinic. He led TME Pharma’s collaborations and partnerships with scientific institutions and big pharma such as Merck, Eli Lilly, Pfizer and Roche. Dirk holds a Doctor in molecular biology from the University of Stuttgart and an MBA from the University of Potsdam.

Karen Ophoff

Vice President

HR & Legal, General Counsel

Karen Ophoff, VP HR & Legal, General Counsel, joined TME Pharma in 2001 and works closely with the entire team. She is entrusted with all legal, corporate, financing & HR matters. 


Karen guided the company’s listing on the Euronext Growth in 2016 and negotiated collaboration and licensing agreements with Merck, Pfizer, Roche and Eli Lilly and academic and research organizations both in Europe and the US. Karen has been involved in raising more than €190 million via diverse vehicles since 2001. Karen studied law at the Freie Universität Berlin and joined TME Pharma after her bar exam.

Ewelina Staniuk

Senior Director

Investor Relations & Business Development

Ewelina Staniuk is Senior Director Investor Relations and Business Development at TME Pharma. She drives investor and partnering discussions and is in charge of corporate communication. Since joining the company in 2018, she has become part of the core team responsible for evaluating new opportunities, financing transactions and biotech and pharma collaborations. 


Ewelina brings to TME Pharma over 10 years’ experience in multi-stakeholder international projects and program management in healthcare and business settings. Prior to TME Pharma, she worked at HIMSS, a global health-tech association, and McKinsey & Company. Ewelina holds an MA in Political Strategy and Communication from the University of Kent.


We use cookies

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (Google Analytics cookies). You can decide for yourself whether you want to accept the cookies. Please note that if you refuse cookies, you may no longer be able to use all of the site's functions.